Laurus Labs and partners to develop pediatric HIV drug

Hyderabad: City-based pharma player Laurus Labs on Tuesday announced that it has entered into an agreement to accelerate the development of second and third-line HIV medication — darunavir boosted with ritonavir (DRV/r) —for children in association with Unitaid and the Clinton Health Access Initiative (CHAI).
Despite being available in high-income countries for over a 15-year period, a generic, fixed-dose combination pediatric version of DRV/r is still not available. Through this agreement, the partners are working towards filling this gap.
The second-and third-line therapies are critical for children living with HIV/AIDS (CLHIV) where the World Health Organization (WHO)-recommended first-line treatment dolutegravir (DTG) may not be an option due to medication resistance or intolerance. Currently available second- and third-line treatments are often difficult for children to take due to bitter taste and difficult forms of administration.
“A pediatric version of DRV/r has been a global health priority since 2013, but is still not available, leaving thousands of children without the lifesaving medication they need,” said Ann Veneman, interim co-CEO of CHAI.
The collaboration between Laurus Labs, CHAI, and Unitaid can positively impact over 1 lakh children living with HIV/AIDS and help them in leading a better life especially in their formative years. Laurus will be provided with financial incentive for a portion of its development and commercialization costs. CHAI will work closely with Laurus Labs to provide technical and regulatory support to enable accelerated generic development and regulatory submission of the medication, said a release.

Source link

Related Articles

Leave a Reply

Back to top button